201 related articles for article (PubMed ID: 34992215)
1. TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas.
Li J; Wang X; Chen L; Zhang J; Zhang Y; Ren X; Sun J; Fan X; Fan J; Li T; Tong L; Yi L; Chen L; Liu J; Shang G; Ren X; Zhang H; Yu S; Ming H; Huang Q; Dong J; Zhang C; Yang X
Cancer Gene Ther; 2022 Aug; 29(8-9):1117-1129. PubMed ID: 34992215
[TBL] [Abstract][Full Text] [Related]
2. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
3. Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth.
Leventoux N; Augustus M; Azar S; Riquier S; Villemin JP; Guelfi S; Falha L; Bauchet L; Gozé C; Ritchie W; Commes T; Duffau H; Rigau V; Hugnot JP
Sci Rep; 2020 Mar; 10(1):5504. PubMed ID: 32218467
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
5. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.
Avsar T; Kose TB; Oksal MD; Turan G; Kilic T
Mol Biol Rep; 2022 Oct; 49(10):9241-9249. PubMed ID: 35934766
[TBL] [Abstract][Full Text] [Related]
7. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
8. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway.
Fu Y; Yao N; Ding D; Zhang X; Liu H; Ma L; Shi W; Zhu C; Tang L
J Cell Physiol; 2020 Mar; 235(3):2761-2775. PubMed ID: 31531884
[TBL] [Abstract][Full Text] [Related]
9. Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation.
Kagawa Y; Umaru BA; Kanamori M; Zama R; Shil SK; Miyazaki H; Kobayashi S; Wannakul T; Yang S; Tominaga T; Owada Y
Mol Oncol; 2022 Jan; 16(1):289-306. PubMed ID: 34716958
[TBL] [Abstract][Full Text] [Related]
10. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
[TBL] [Abstract][Full Text] [Related]
11. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
15. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
16. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
18. CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
Wang S; Wu J; Zhao W; Li M; Li S
FASEB J; 2023 Apr; 37(4):e22848. PubMed ID: 36906285
[TBL] [Abstract][Full Text] [Related]
19. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
20. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
